Skip to main content

Table 1 Summary of HGF/Met alterations in breast cancer

From: The Met oncogene and basal-like breast cancer: another culprit to watch out for?

Reference Observations/lesions Clinical/biological aspects
Yao and colleagues [21] High levels of HGF in breast tumor tissue Invasive ductal carcinomas
Tuck and colleagues [16] HGF/Met autocrine loop in tumor cells Co-localization at the advancing margins of the tumors
Jin and colleagues [22] High levels of HGF and c-Met overexpression in breast tissue Invasive ductal carcinomas
Camp and colleagues [24] Met overexpression Reduced survival, relapse and metastatic dissemination
Edakuni and colleagues [23] Met overexpression High histological grade, proliferative index, advancing margins
Kang and colleagues [82] High levels of Met and HGF in node-negative breast cancer Tumor progression and poor patient outcome
Lengyel and colleagues [83] Met overexpression in node-positive breast cancer Disease progression and decrease in disease-free survival
Charafe-Jauffre and colleagues [43] Met overexpression in breast cancer cell lines Basal-like phenotype
Lindemann and colleagues [84] Imbalance in Met expression between tumor and normal tissue Aggressive ductal carcinoma in situ
Eichbaum and colleagues [85] High HGF serum levels Liver metastatic colonization from breast cancer
Garcia and colleagues [45] Met overexpression in tissue microarrays Poor prognosis, basal-like phenotype
Finkbeiner and colleagues [49] Transcriptional upregulation of Met Anchorage-independent growth of basal-like breast cancer cells
Smolen and colleagues [65] Met amplification in a Brca1-p53 mouse model of breast cancer Mouse mammary tumor progression
Ponzo and colleagues [53] MMTV-Met mutant transgenic mice Heterogeneous mammary tumors, basal-like phenotype
Graveel and colleagues [52] Met mutant knock-in mice Mammary tumors associated with basal-like phenotype
  1. HGF, hepatocyte growth factor; MMTV, mouse mammary tumor virus promoter.